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Sulfated Hyaluronan Derivatives 
Modulate TGF-β1:Receptor 
Complex Formation: Possible 
Consequences for TGF-β1 Signaling
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Stephanie Moeller5, Matthias Schnabelrauch5, Jörg Rademann4, Ute Hempel3, M. Teresa 
Pisabarro2, Dieter Scharnweber1 & Vera Hintze1
Glycosaminoglycans are known to bind biological mediators thereby modulating their biological 
activity. Sulfated hyaluronans (sHA) were reported to strongly interact with transforming growth factor 
(TGF)-β1 leading to impaired bioactivity in fibroblasts. The underlying mechanism is not fully elucidated 
yet. Examining the interaction of all components of the TGF-β1:receptor complex with sHA by surface 
plasmon resonance, we could show that highly sulfated HA (sHA3) blocks binding of TGF-β1 to its TGF-β 
receptor-I (TβR-I) and -II (TβR-II). However, sequential addition of sHA3 to the TβR-II/TGF-β1 complex 
led to a significantly stronger recruitment of TβR-I compared to a complex lacking sHA3, indicating 
that the order of binding events is very important. Molecular modeling suggested a possible molecular 
mechanism in which sHA3 could potentially favor the association of TβR-I when added sequentially. 
For the first time bioactivity of TGF-β1 in conjunction with sHA was investigated at the receptor level. 
TβR-I and, furthermore, Smad2 phosphorylation were decreased in the presence of sHA3 indicating 
the formation of an inactive signaling complex. The results contribute to an improved understanding of 
the interference of sHA3 with TGF-β1:receptor complex formation and will help to further improve the 
design of functional biomaterials that interfere with TGF-β1-driven skin fibrosis.
Transforming growth factor (TGF)-β1 is a member of the TGF-β superfamily that consists of structurally 
and functionally related cytokines including three different forms of TGF-β, the bone morphogenetic pro-
teins (BMPs), nodals, activins, inhibins and growth differentiation factors1–3. These cytokines are produced 
by diverse cell types, e.g. fibroblasts, endothelial cells as well as immune cells, and are known to regulate cell 
migration, adhesion, proliferation and differentiation4, 5. Members of the TGF-β superfamily signal across cell 
membranes in a distinctive manner by assembling heterotetrameric complexes of structurally related serine/
threonine-kinase receptor pairs6. Among the TGF-β family, activins and nodals as well as BMPs promiscuously 
share type I and type II receptors whereas the TGF-βs interact with their receptors specifically6–9. TGF-β receptor 
type II (TβR-II) has high affinity for the dimeric TGF-β while TGF-β type I receptor (TβR-I) does not, despite 
the presence of a ligand binding domain7, 10. The different affinities of TβR-II and TβR-I to the ligand dictate a 
sequential order of complex assembly11 where TGF-β1 binds to TβR-II first and they both form a composite 
interface for the recruitment of TβR-I7–9. Upon binding of TGF-β, TβR-II trans-phosphorylates the low-affinity 
TβRI6, 12, 13. Activated type I receptors proceed to phosphorylate the cytoplasmic effector proteins Smad2 and 
Smad3 resulting in Smad4-containing heteromeric complexes of Smads 2 and 3, which are then translocated to 
the nucleus to regulate transcription of numerous target genes2, 14–16. In addition, TGF-β1 can activate specific 
non-Smad signaling pathways belonging to the mitogen-activated protein kinase pathways, including extra-
cellular signal-regulated kinase 1/2 (Erk1/2)17. TGF-β1 is a key regulator of the production and remodeling of 
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extracellular matrix (ECM) and plays a critical role in all phases of wound healing as it has a distinct influence on 
the regulation of multiple cellular responses. It is found at high levels in the wound microenvironment, where it 
promotes fibroblast chemotaxis, myofibroblast differentiation and induces fibroblasts to synthesize and contract 
extracellular matrix for wound contraction1, 2. Consistent overexpression of TGF-β1 during wound healing leads 
to an excessive accumulation of ECM proteins which clinically manifests in fibrotic skin disorders, like hyper-
trophic scarring, keloids and localized or systemic sclerosis18–20. TGF-β1 is known to interact with heparin and 
heparan sulfate (HS). Binding to these glycosaminoglycans (GAGs) potentiates TGF-β1 activity and prevents 
proteolytic degradation in vitro21, 22. Hintze et al. demonstrated specific interactions between chemically sulfated 
hyaluronan HA (sHA) derivatives and TGF-β1 where the respective binding strength depended on the degree 
of HA sulfation and the highly sulfated HA (sHA3, three sulfate groups per repeating disaccharide unit of HA) 
exhibited the strongest interaction with TGF-β123. In previous studies sHA derivatives have been shown to be a 
promising tool for investigating the structure-function relationship of GAGs in their interaction with biological 
mediators23–28. Compared to natively sulfated GAGs such as heparin they have defined properties regarding their 
monosaccharide composition and sulfation. Van der Smissen et al. investigated the consequences of TGF-β1 
interaction with sHA derivatives on its bioactivity in vitro29. They revealed an impaired Smad2/3 translocation to 
the nucleus in the presence of sHA3 in human dermal fibroblasts and proposed that sHA prevents interaction of 
TGF-β1 with TβR-I and -II. In the present study, the impact of sHA on the TGF-β1:receptor complex formation 
was investigated to explain the reduced TGF-β1 bioactivity. Using surface plasmon resonance (SPR) combined 
with molecular docking and molecular dynamics simulation techniques the complex interaction of TGF-β1 and 
both TGF-β receptors with sHA derivatives were examined for the first time. Moreover, the consequences of 
TGF-β1/GAG interaction and altered TGF-β1:receptor complex formation for TGF-β1-mediated TβR-I phos-
phorylation was examined using Western Blot analysis. In addition, TGF-β1-induced phosphorylation of Smad2 
and Erk1/2 was evaluated.
Results
Characterization of Polymeric HA Derivatives. Low-, medium- and high-sulfated HA derivatives 
(sHA1, D.S. = 1.0; sHA2, D.S. = 1.8; sHA3, D.S. = 2.8) with reduced molecular weight (MW (LLS) of 26 kDa, 
29 kDa and 21 kDa, respectively) were synthesized and characterized as described previously24, 29. As a non-sul-
fated reference material, a low molecular weight HA with a molecular weight of MW (LLS) of about 48 kDa was 
prepared by controlled thermal degradation of native high molecular weight HA. 13C-NMR investigations of this 
degraded HA did not show any structural changes compared to native HA.
Characterization of Tetrameric HA Derivatives. The persulfated and anomerically fixed HA degree of 
polymerization (dp) 4 was characterized by proton and carbon NMR-spectroscopy. The signals of the sugar ring 
showed the expected downfield shifts in the range of e.g. 0.46–0.61 ppm for the anomeric protons compared to 
the non-sulfated azide of HA dp4. The mass spectrometric analysis required a counter-ion exchange of all sulfate 
residues from sodium to tetraethylammonium (TEA) to reduce sulfate loss during the ionization process. The 
obtained ESI-MS-spectra of the per-sulfated azide of HA dp4 showed multiple charged species and different num-
bers of attached TEA counter-ions as described in Köhling et al.30. The average sulfate content of 80% of all mass 
signals that were detected and assigned amounted to a value of 8.8 sulfate groups per ion.
SPR Analysis of TGF-β1 Binding to TβR-I and TβR-II after Pre-incubation with GAG 
Derivatives. The impact of TGF-β1/GAG interaction on the TGF-β1:receptor complex formation was 
analyzed via SPR. Single TβRs were immobilized onto sensor chip surfaces and their interaction with TGF-β1 
pre-incubated with different concentrations of HA derivatives was evaluated. While GAG derivatives alone did 
not bind to TβRs, increasing concentration and sulfation of the sHA derivatives led to a significantly decreased 
binding of TGF-β1 to TβR-II (Fig. 1B) and TβR-I (Fig. 1C). sHA3 had the most pronounced impact of all sHA 
derivatives studied. The binding response of TGF-β1 to TβR-II decreased with increasing concentrations of poly-
meric sHA3 but only up to a concentration of 20 µM related to the molecular weight of disaccharide units (D.U.). 
At concentrations above 20 µM D.U. the binding response increased again and ultimately reached a plateau at 
concentrations above 200 µM D.U. (Fig. 1D). At concentrations above 20 µM D.U. a change in the binding curves 
for TGF-β1 binding to TβR-II was detected, where the typical shape changed to a linear and monotonously rising 
one. This effect was also observed for TGF-β1 pre-incubated with sHA2 but not for sHA1 and HA (Supplementary 
Figure S1). In contrast to the findings for TβR-II, binding of TGF-β1 to TβR-I was completely suppressed in the 
presence of 20 µM D.U. sHA3 (Fig. 1E). To determine the minimal binding sequence required to interfere with the 
interaction of TGF-β1 and its receptors HA dp4 and persulfated HA (psHA) dp4 were used. psHA dp4 inhibited 
binding of TGF-β1 to the TβRs as well (Fig. 2). As for the polymeric HA derivatives the effect on TGF-β1 binding 
to TβR-I was more pronounced compared to TβR-II. In contrast, HA dp4 only slightly inhibited the binding of 
TGF-β1 to its receptors and did not exhibit a concentration-dependent effect.
Sequential SPR Analysis of TGF-β1:Receptor Complex Formation in the Presence of Different 
GAG Derivatives. The impact of HA derivatives on the sequential formation of the TGF-β1:receptor com-
plex containing both receptors was investigated. TβR-II was immobilized on a sensor chip surface and the other 
components were injected sequentially in the following order: 40 nM TGF-β1, 100 µM D.U. GAG and 40 nM 
TβR-I. The recruitment of TβR-I to the complex of TβR-II/TGF-β1/sHA3 was significantly enhanced, compared 
to complexes with no GAG derivative (TGF-β1, buffer, TβR-I, Fig. 3B and D). A similar effect occured for psHA 
dp4, when injected in the same sequential order (Fig. 3C and E). When pre-formed TGF-β1/sHA3 complexes 
where injected first followed by the injection of TβR-I, recruitment of TβR-I to the complex was enhanced as well, 
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although the binding of TGF-β1/sHA3 pre-formed complexes to TβR-II was lower compared to TGF-β1 alone 
(Fig. 3B). For both polymeric HA and HA dp4 there was no enhanced TβR-I recruitment.
Molecular Modeling of the TGF-β1/TβR-I/TβR-II/GAG System. Docking calculations and MD sim-
ulations were carried out to investigate the molecular mechanism of enhanced TβR-I recruitment to the complex 
of TβR-II/TGF-β1/sHA3 found in SPR measurements. When docking GAGs to TGF-β1/TβR-II, we found poorly 
clustered and broadly distributed docking solutions (Fig. 4A, upper panel). Some of them spatially overlapped 
with the TβR-I binding site and for this reason could not be used to explain the experimental results obtained for 
TβR-I recruitment. Binding poses corresponding to the obtained loose clusters non-overlapping with the TβR-I 
binding site were extracted for further analysis using an MD approach and free energy calculations. GAGs in 
these binding poses did not promote the association of TGF-β1/TβR-II/GAG with TβR-I. However, when docked 
to TGF-β1/TβR-II/TβR-I, a clear GAG binding pose could be predicted (Fig. 4A, down panel). Analyzing dock-
ing solutions obtained for the TGF-β1/TβR-II/GAG complex, we found the same binding pose within the top 50 
solutions, though, in this case, it was not representative in terms of clustering. MD analysis of this binding pose 
showed that it energetically favors the association of TGF-β1/TβR-II/GAG with TβR-I in case of HA463′ but not 
in case of HA, and that the corresponding interactions are electrostatically driven (Table 1). Analysis of the per 
residue impact to TGF-β1/TβR-II/TβR-I/GAG complex association showed that residue Lys40 of TβR-I (Fig. 4B) 
plays a key role for the interactions with a pre-bound GAG through its carboxyl and sulfate groups.
Figure 1. Binding of TGF-β1 to immobilized TβR-II and TβR-I after pre-incubation with different GAG 
derivatives. (A) Schematic drawings of the experimental set-up. (B) Relative binding of 40 nM TGF-β1 to 
TβR-II alone and after pre-incubation with 2 and 20 µM D.U. of HA, sHA1, sHA2 as well as sHA3. (C) Relative 
binding of 120 nM TGF-β1 to TβR-I alone and after pre-incubation with 100 nM D.U. of HA, sHA1, sHA2 as 
well as sHA3. (D) Sensorgrams for the binding of 40 nM TGF-β1 to TβR-II or (E) 120 nM TGF-β1 to TβR-I 
alone, after pre-incubation with 0.1, 2, 20 and 200 µM D.U. of sHA3 and for 200 µM D.U. of sHA3 without 
TGF-β1. For (B) and (C) values represent the mean ± SD of n = 3. One-way ANOVA: *p < 0.05; ***p < 0.001 
vs. HA; ##p < 0.01; ###p < 0.001 vs. TGF-β1 only. For (D) and (E) one representative sensorgram out of three 
measurements is shown.
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Influence of GAG Derivatives on TGF-β1-mediated TβR-I and Smad2 Phosphorylation. Previous 
experiments showed that TGF-β1:receptor complex formation was altered in the presence of sHA3. Western Blot 
analyses were performed to determine the consequences of this change on the phosphorylation of TβR-I and the 
second messenger molecules Smad2 and Erk1/2. Hs27 fibroblast cells treated with 10 ng/ml TGF-β1 displayed 
a strong Smad2 phosphorylation signal compared to the unstimulated control. Stimulation with pre-formed 
TGF-β1/sHA3 complexes led to a decrease in TGF-β1-mediated Smad2 phosphorylation at all time points inves-
tigated, which was significant after 5 min (Fig. 5A and B). TβR-I was already phosphorylated in untreated cells, 
but was enhanced in the presence of 10 ng/ml TGF-β1. Treatment with TGF-β1/sHA3 complexes reduced TβR-I 
phosphorylation compared to the total amount of TβR-I, although the differences are not significant (Fig. 5A and 
C). Regarding the phosphorylation of Erk1/2 no influence of sHA3 was observed (Supplementary Figure S2).
Discussion
Chemically sulfated HA derivatives are promising candidates for engineering functional biomaterials since their 
sulfate groups modulate binding and bioactivity of growth factors, which in turn can influence healing processes. 
Previous studies by van der Smissen et al. showed sHA derivatives to impair TGF-β1 downstream signaling by 
reducing Smad2/3 translocation to the nucleus. In silico docking experiments suggested that occupation of the 
receptor binding sites on TGF-β1 by sHA might be responsible for this effect29. The aim of the present study was 
twofold: to achieve better understanding of sHAs’ impact on TGF-β1:receptor complex formation by combining 
SPR analysis and computational approaches and to determine the consequences of an altered TGF-β1:receptor 
complex formation on the receptor level by investigating TβR-I phosphorylation in addition to phosphorylation 
of the TβR-I regulated effector protein Smad215. Studies by Hintze et al. revealed that TGF-β1 interacts with sHA 
derivatives in a sulfation- dependent manner, demonstrating the strongest interaction with highly sulfated 
sHA323. In the present study, pre-incubation of TGF-β1 with sHA derivatives blocked the binding of TGF-β1 in 
particular to TβR-I, but also to TβR-II. sHA3 exhibited the strongest inhibitory effect and completely blocked 
binding of TGF-β1 to TβR-I at 20 µM D.U., while binding to TβR-II was not fully constrained even at concentra-
tions above 200 µM D.U. sHA3. This is in line with the low affinity of TβR-I for the ligand alone (KD = 70 µM), 
Figure 2. Binding of TGF-β1 to immobilized TβR-II and TβR-I after pre-incubation with tetrameric GAG 
derivatives. (A) Relative binding of 40 nM TGF-β1 to TβR-II alone and after pre-incubation with 0.1, 2, 20 and 
200 µM D.U. of HA dp4 and psHA dp4. (B) Relative binding of 120 nM TGF-β1 to TβR-I alone and after pre-
incubation with 0.1, 2, 20 and 200 µM D.U. of HA dp4 and psHA dp4. Values represent the mean ± SD of n = 3. 
Two-way ANOVA: *p < 0.05; ***p < 0.001 vs. respective treatment; #p < 0.05; ###p < 0.001 vs. TGF-β1 only.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 1210  | DOI:10.1038/s41598-017-01264-8
while the affinity of TβR-II is considerably higher (KD = 190 nM)31. In our experiments, the lower affinity of TβR-I 
was reflected by the fact that a three times higher concentration of TGF-β1 was needed to receive a binding 
response for TβR-I comparable to TβR-II. However, inhibition of binding to TβR-I might not be as relevant as to 
TβR-II, since interactions between TGF-β1 and TβR-I in vivo are barely detectable31. The SPR data are consistent 
with observations from previous studies including TGF-β1 and sHA derivatives predicting a sulfation-dependent 
occupation in particular of the TβR-I binding site of TGF-β1 by tetrameric sHA derivatives29. sHA preferred the 
TβR-I binding site on TGF-β1 due to a more favorable distribution of positively charged residues, which are 
important for GAG recognition. Longer GAG molecules bound to the TβR-I site might impair binding of the 
ligand to the TβR-II site as well, since the binding sites are in close proximity and thus sterical hindrance could 
occur. In binding experiments of the present study psHA dp4 exhibited a strong inhibitory effect on the associa-
tion of TGF-β1 and TβR-II as well, though weaker than the effect on TGF-β1 binding to TβR-I. The interference 
of GAGs with TβR-I binding was dependent on GAG net charge indicating the importance of electrostatics in 
these interactions. Interestingly, an increase in binding response for binding of TGF-β1 to TβR-II could be 
observed in the presence of sHA3 at concentrations above 20 µM D.U. compared to lower sHA3 concentrations. 
Moreover, the curvature in the sensorgrams was different for binding of TGF-β1 to TβR-II in the absence of 
sHA3. The slope of the binding curves was more linear and binding to TβR-II did not further decrease. TGF-β1 
and sHA3 might have formed complexes that were able to bind TβR-II even though the binding strength was 
weaker than for TGF-β1 alone. This is consistent with previous docking experiments revealing that GAGs only 
partially impair TGF-β1 binding to TβR-II29. As TGF-β1:receptor complex formation is described as an 
ordered-sequential assembly mode sequential SPR experiments were performed. In vivo, the different affinities of 
TβR-II and TβR-I to the ligand dictate a sequential order of complex assembly: TGF-β1 binds TβR-II first, fol-
lowed by the recruitment of TβR-I8, 9. Interestingly, a significantly stronger interaction of TβR-I with the 
Figure 3. Sequential TGF-β1:receptor complex formation in the presence of different HA derivatives. (A) 
Schematic drawing of the experimental set-up showing that TβR-II was immobilized on a C1 Sensor Chip and 
all other components were injected in the order: TGF-β1, GAG or buffer, TβR-I. Binding of TβR-I to TβR-II/
TGF-β1 in the presence of (B) polymeric HA and sHA3 or (C) HA dp4 and psHA dp4. The sensorgrams 
display one representative experiment out of at least three independent measurements. Binding levels for the 
association of TβR-I to the complex of TβR-II/TGF-β1 including the indicated (D) polymeric or (E) tetrameric 
GAGs were ranked. Values represent the mean ± SD of n = 3. One-way ANOVA: *p < 0.05; **p < 0.01 vs. 
control or HA.
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complexes of TβR-II/TGF-β1/sHA3 and TβR-II/TGF-β1/psHA dp4 was observed, which did not occur in the 
presence of HA or HA dp4. In contrast to our findings with pre-formed TGF-β1/sHA complexes, binding of 
TβR-I to TβR-II/TGF-β1/sHA3 was not blocked by sHA3, but the interaction was enhanced compared to TβR-I 
binding to TβR-II/TGF-β1. Thus, when TGF-β1 and sHA3 were injected consecutively, TGF-β1 bound to TβR-II 
still had free binding sites for sHA3. A similar effect was observed with psHA dp4, even though the recruitment 
was lower compared to polymeric sHA3. When TGF-β1 and sHA3 were injected as pre-formed complexes over 
immobilized TβR-II in the sequential experiments TβR-I recruitment to the complex of TβR-II/TGF-β1/sHA3 
was enhanced as well. This further indicates that TGF-β1/sHA3 complexes with sHA3 concentrations above 
20 µM D.U. were able to bind TβR-II. In general, the binding levels for this interaction were low, due to a lower 
immobilization level of TβR-II. However, a stable binding of TGF-β1/sHA3 complexes to TβR-II was already 
shown in Fig. 1D. Recruitment of TβR-I was still enhanced, but due to the lower binding response of pre-formed 
TGF-β1/sHA3 complexes the effect was less pronounced compared to consecutively injected TGF-β1 and sHA3 
showing a higher binding signal. Molecular modeling supported the sequential SPR findings and provide further 
insights into the potential molecular mechanism underlying the effect of GAG recognition on the function of 
TGF-β1:receptor:GAG system. There were different binding poses for GAGs depending on the presence or 
absence of the receptors. If the TβRs were not included in the docking experiment, GAGs interfered with the 
TGF-β receptor binding sites. However, inclusion of the receptors led to alternative putative binding poses for the 
GAGs. In the presence of TβR-II alone these were broadly distributed, but if TβR-I was included a clear binding 
Figure 4. Molecular Modeling of the TGF-β1/TβR-I/TβR-II/GAG System. (A) Docking results for HA463′ dp4 
(top 50 solutions, in blue sticks) to TGF-β1/TβR-II (top) and TGF-β1/TβR-II/TβR-I (bottom). TGF-β1 is shown 
in yellow, TβR-II in green and TβR-I in grey. The part of the system not used for docking calculations (TβR-I 
and TβR-II on the right side of TGF-β1) is depicted with transparency. (B) Zoomed view of the residue Lys40 
of TβR-I (in thick sticks, carbons in cyan) that interacts with the negatively charged groups of HA463′ dp4 (in 
thick sticks, carbons in orange). Protein is shown in cartoon.
System ΔG, kcal/mol **ΔGelect, kcal/mol
ΔGK40, kcal/
mol
TGF-β1/TβR-II/TβR-I −68.9 ± 12.5 −301.3 ± 28.9 0.2
TGF-β1/TβR-II/HAdp4/TβR-I* −63.3 ± 12.9 −415.9 ± 35.4 0.0
TGF-β1/TβR-II/HAdp8/TβR-I −83.1 ± 9.6 −435.3 ± 39.1 −3.3
TGF-β1/TβR-II/HA463′dp4/TβR-I −83.1 ± 8.4 −420.0 ± 48.1 −2.7
TGF-β1/TβR-II/HA463′dp8/TβR-I −84.9 ± 12.7 −451.1 ± 76.7 −2.9
Table 1. MM-PBSA analysis of TβR-I binding to TGF-β1/TβR-II in the presence and absence of GAGs. *GAG 
did not behave stable in the MD and dissociated; **Electrostatic component.
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pose emerged. Furthermore, sHA oligosaccharides led to a more stable interaction with TβR-I than non-sulfated 
HA oligosaccharides if pre-bound to TβR-II/TGF-β1. This could be explained by electrostatic interactions of the 
GAGs carboxyl and sulfate groups with Lys40 of TβR-I. The interaction was stronger for GAGs with a high sulfa-
tion degree (3 vs. 0) and chain length (dp8 vs dp4). sHA showed no clear binding pose in the complex with 
TβR-II/TGF-β1 in the absence of TβR-I. This may indicate multiple binding sites of the GAG on TGF-β1 that 
allow for TβR-I association to the complex. Lyon et al. proposed a binding model in which GAG binding occurs 
at two distinct sites on the TGF-β1 dimer, which was confirmed by Lee et al., postulating that the second binding 
site is located on the face opposite of the primary binding site21, 32. Even if TβR-I association was increased the 
complex that formed in the presence of sHA3 was inactive as Western Blot experiments revealed an impaired 
Smad2 phosphorylation in the presence of sHA3. Immunofluorescence staining of Smad2/3 in primary 
Figure 5. Influence of sHA3 on the TGF-β1-mediated TβR-I and Smad2 phosphorylation. Hs27 fibroblast cells 
were stimulated with 10 ng/ml TGF-β1 (0.4 nM) alone or pre-formed complexes of TGF-β1 and 100 µg/ml sHA3 
(130 µM D.U.) for the indicated time points. Cells were lysed and applied to Western Blot analyses using specific 
anti-phospho-Smad2, anti-phospho-TβR-I and anti-GAPDH antibodies. Membranes were reblotted afterwards 
with anti-TβR-I antibody. For every time point a representative blot is shown (A). The time course of TGF-β1-
mediated phosphorylation in the presence or absence of sHA3 is plotted for Smad2 phosphorylation (B) and 
TβR-I phosphorylation relative to unstimulated cells (C). Two-way ANOVA: ***p < 0.001 vs. TGF-β1 only.
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fibroblasts incubated with sHA3 showed a reduced translocation of the second messengers to the nucleus29 which 
is in line with our data showing a reduced Smad2 phosphorylation in a fibroblast cell line. In addition, a trend for 
a decreased TβR-I phosphorylation in the presence of sHA3 was observed as well. In the TGF-β1 pathway, Smad2 
and Smad3 are receptor-regulated effector proteins, specifically phosphorylated by activated TβR-I15. A reduced 
Smad2 phosphorylation would thereby be coherently explained by a previously reduced receptor phosphoryla-
tion due to altered TGF-β1:receptor formation. For the phosphorylation of Erk1/2, however, no impact of GAGs 
could be observed. This might be due to Erk1/2 being regulated by a multitude of other factors and not being 
activated by the Smad pathway33, 34. Binding studies with the sulfated polysaccharide fucoidan showed an inhibi-
tory effect on the binding of TGF-β1 to TβR-II resulting in a decreased Smad2 phosphorylation as well35. 
However, in this study a three times lower concentration of sulfated polysaccharide was used compared to the 
present study, and TβR-I was not included in the binding studies. In contrast to this, Lyon et al. found that heparin 
and highly sulfated liver HS potentiated the activity of TGF-β1 in rat kidney fibroblasts, indicating that there is no 
competition between GAG binding and receptor binding but some form of cooperativity. Nevertheless, the effect 
was only observed in the presence of α2-macroglobulin (α2M) and therefore ascribed to an antagonistic effect of 
heparin and HS rescuing the inactivation of TGF-β1 by α2M, rather than to the modulation of TGF-β1:receptor 
interaction21, 36. Chemically sulfated dextrans were also found to potentiate the biological activity of TGF-β1, but 
this was explained by a mere protection of TGF-β1 from proteolysis upon complex formation with dextrans37. It 
should also be taken into account that conclusions are based on cell experiments with mink lung epithelial cells. 
We recognize that our study has potential limitations. The receptors used for SPR experiments are Fc-fusion pro-
teins. As these receptor chimera are dimeric avidity through bivalent interactions cannot be excluded in sequen-
tial SPR experiments and TβR-II and TβR-I might form a ligand-independent complex in addition to complexes 
including TGF-β1. The enhanced TβR-I recruitment, however, is ligand-dependent as sHA derivatives do not 
bind to the receptors. Another potential limiting factor may be the fact that native TGF-β receptors are trans-
membrane receptors with a cytoplasmic tail involved in large functional complexes. Our study only uses the 
ECDs of the receptors in a simplified in vitro model, allowing only for a part of the complex interplay of the com-
ponents in vivo. The present study reveals the underlying mechanism of reduced TGF-β1 bioactivity in fibroblast 
cells in the presence of sHA3. The findings have a strong impact on the elucidation of the mode of action of sHA 
derivatives, showing that they affect the association of TGF-β1 with both TGF-β receptors and that the order of 
binding events is highly important. By interacting with TGF-β1 GAGs subsequently alter TGF-β1:receptor com-
plex formation either by blocking the interaction of TGF-β1 with its receptor or by partially forming a complex 
that does not activate the Smad signaling pathway. Together with van der Smissen et al. our data suggest that sHA 
derivatives are promising candidates for biomaterials as their inhibitory effect on TGF-β1 bioactivity might be 
useful to locally interfere with TGF-β1 driven skin fibrosis. Whether our in vitro findings can be translated in vivo 
needs to be evaluated extensively in future work.
Methods
Materials. Hyaluronan (from Streptococcus, MW = 1.1 × 106 g mol-1) was obtained from Aqua Biochem 
(Dessau, Germany) and sulfur trioxide/dimethylformamide complex (SO3–DMF, purum, ≥97%, active 
SO3 ≥ 48%) as well as sulfur trioxide/pyridine complex (SO3–pyridine, pract.; ≥45% SO3) from Fluka Chemie 
(Buchs, Switzerland). Biochemical agents were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Recombinant human TGF-β1 (240-B-010/CF) as well as recombinant human TGF-β receptor II/Fc Chimera 
(341-BR-050/CF) were obtained from R&D Systems (Wiesbaden-Nordenstadt, Germany) and recombinant 
human TGF-β receptor I/Fc Chimera (10459-H03H) from Hoelzel Diagnostika GmbH (Köln, Germany). For 
SPR measurements the Series S Sensor Chip C1, the Amine Coupling Kit and HBS-EP (10x) from GE Healthcare 
Europe GmbH (Freiburg, Germany) were used.
Preparation of Polymeric HA Derivatives. Low molecular weight HA (LMW-HA) was produced via 
thermal degradation of native high molecular HA as described previously in Kunze et al.38 Low-, medium- and 
high-sulfated HA derivatives (sHA1, sHA2, sHA3) were synthesized and analytically characterized as described 
in Hintze et al.23, 24. Analytical data of the prepared HA derivatives (LMW-HA, sHA1, sHA2, sHA3) are summa-
rized in Table 2.
Preparation of Tetrameric HA Derivatives. Non-sulfated HA tetrasaccharide (degree of polymerization 
(dp) 4) was produced via enzymatic digestion of native HA with bovine testes hyaluronidase. Persulfated HA 
dp4 was synthesized after fixation of the anomeric configuration of the reducing end as azide with 2-chloro-1
Sample LMW-HA sHA1 sHA2 sHA3
D.S.a — 1.0 1.8 2.9
Mn [g/mol]b 28.250 (81.145) 18.260 (46.935) 14.980 (34.335) 11.680 (28.885)
Mw [g/mol]c 48.255 (187.010) 26.610 (102.730) 29.040 (72.520) 20 950 (47.720)
PDd 2.3 2.2 2.1 1.7
Table 2. Characteristics of synthesized polymeric HA derivatives. aD.S.: degree of sulfation, average number 
of sulfate groups per disaccharide unit of GAG. bMn: number-average molecular weight, determined by Laser 
Light Scattering (LLS) detection and Refraction (RI) detection (in brackets). cMw: weight-average molecular 
weight, determined by LLS detection and RI detection (in brackets). dPD: polydispersity index based on the 
values calculated from RI detection.
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,3-dimethyl-imidazolinium chloride and sodium azide in the presence of N-methylmorpholine as base. The 
hydroxyl groups of the corresponding anomeric azide were chemically sulfated using sulfur trioxide pyridine 
complex as sulfating agent. After purification by dialysis, HA dp4 was obtained as nona-sulfate sodium salt 
(psHA, dp4) as described in Köhling et al.30.
Immobilization of TβR-II and TβR-I on Sensor Chips. For interaction analysis of growth factor and 
receptors in the presence of GAGs, a BIACORE T100 instrument (GE Healthcare) was used. TβR-II and TβR-I, 
respectively, were immobilized on the surface of a Series S Sensor Chip C1 at 25 °C using the amine coupling reac-
tion as described by the manufacturer resulting in an average of 200 RU TβR-II and 130 RU TβR-I immobilized to 
the chip surface using a concentration of 100 µg/ml. As a reference one flow cell was activated and directly deac-
tivated without immobilizing the receptors. HBS-EP (0.01 M HEPES (pH 7.4), 0.15 M NaCl, 3 mM EDTA, 0.05% 
surfactant P20) was used as running buffer. Prior to interaction analysis, the chip surface with immobilized recep-
tors was blocked with three injections of 1% (w/v) BSA, 5% (w/v) sucrose in HBS-EP (3 × 700 s at 30 µl/min).
SPR Analysis of TGF-β1 Binding to TβR-I and TβR-II in the Presence of GAG Derivatives. All 
interaction studies were performed at 37 °C. GAG samples were diluted in HBS-EP. For interaction studies with 
TβR-II 100 nM-200 µM of the respective GAG derivative related to the molecular weight of disaccharide units 
(D.U.) were pre-incubated for 60 min at room temperature (RT) with 40 nM TGF-β1 in HBS-EP. For the analysis 
of binding to TβR-I 100 nM D.U. GAG were pre-incubated for 60 min at RT with 120 nM TGF-β1 in HBS-EP. 
After three start up injections with running buffer, pre-formed TGF-β1/GAG complexes or TGF-β1 alone were 
injected for 120 s at 30 µl/min and binding levels were recorded 10 s before injection stop. Additionally, 200 µM 
D.U. GAG alone were injected over the immobilized TβRs as a control. The injection was followed by a 10 min 
dissociation phase in running buffer at a flow rate of 30 µl/min. The sensor chip surface was regenerated after each 
sample injection with 20 mM HCl for 2 min at a flow rate of 5 µl/min39. The baseline was allowed to stabilize for 
1000 s with running buffer prior to injection of the next sample. Data represent the mean of three independent 
measurements.
Sequential SPR Analysis of TGF-β1:Receptor Complex Formation in the Presence of Different 
GAG Derivatives. TβR-II was immobilized on the sensor chip surface and three consecutive injections of 
TGF-β1, GAG derivatives and TβR-I were performed in each running cycle. 40 nM TGF-β1 were injected for 
120 s at 30 µl/min with a dissociation phase of 30 s in running buffer. Afterwards 100 µM D.U. of the respective 
GAG derivative were injected under the same conditions followed by the injection of 40 nM TβR-I with a dis-
sociation time of 300 s. Additionally, 40 nM TGF-β1 and 100 µM D.U. of the respective GAG derivative were 
pre-incubated for 1 h at RT. The pre- formed growth factor/GAG complexes were injected over immobilized 
TβR-II, followed by a buffer injection and the injection of TβR-I. The sensor chip surface was regenerated after 
each running cycle with a 30 µl pulse of 5 M NaCl in 30 mM NaOH followed by two injections of 20 mM HCl 
for 120 s at a flow rate of 5 µl/min. Data were double referenced by the response of the reference surface and the 
response of HBS-EP buffer alone relative to a baseline report point. Binding parameters were evaluated using the 
BIACORE T100 evaluation software 2.03.
Molecular Docking. Autodock 3 (AD3)40 was used for docking GAG molecules to TGF-β1/TβR-II and 
TGF-β1/TβR-II/TβR-I complexes. The protein and receptor coordinates were obtained from their experimen-
tal crystal structure at the Brookhaven Protein Databank (PDB ID: 3KFD, 2.99 Å). HA (-GlcU-GlcNAc-)n and 
HA463′ (-GlcU3S-GlcNAc4S6S-)n of length dp4 and dp8 were left completely flexible in the docking runs. An 
atomic grid with the 0.375 Å spacing was used. 100 independent runs of the Lamarckian genetic algorithm with 
an initial population size of 300 and a termination condition of 105 generations or 9995·105 energy evaluations 
were carried out. The 50 top docking solutions were clustered using the DBSCAN algorithm41.
Molecular Dynamics. The TGF-β1/TβR-I/TβR-II complex and the complexes with GAGs obtained by dock-
ing were simulated with the AMBER 11.0 package42 using ff99SB force field parameters for the protein molecule 
and GLYCAM06 for GAG molecules. These complexes were solvated with TIP3P water molecules in an octahe-
dral periodic box with a minimal distance to the periodic box border of 6 Å and neutralized by counterions. The 
molecular dynamics (MD) simulations were run as described previously43 with MD productive runs of 10 ns. 
MM-PBSA free energy calculations of protein-GAG binding and MM-GBSA (igb = 2) per residue energy decom-
position were done for 100 frames evenly distributed in each MD trajectory.
Cell Culture and Western Blot Analysis of TβR-I Phosphorylation. Hs27 fibroblast cells 
(ATCC-CRL-1634, human foreskin fibroblast cell line) were cultivated in complete medium (Dulbecco’s Modified 
Eagle’s Medium) with 10% fetal calf serum, 1,5 g/l NaHCO3, 1% Penicillin/Streptomycin, 100 mM sodium 
pyruvate and 4 mM L-glutamine (Biochrom AG, Berlin, Germany) at 37 °C in a humidified atmosphere with 
5% CO2. For experiments cells were seeded at a density of 13,000 cells/cm2 in T75 cell culture flasks (Sarstedt, 
Nümbrecht, Germany), grown to 80% confluency and serum-starved for 24 h. Cells were stimulated with 10 ng/
ml (0.4 nM) TGF-β1 alone or with mixtures of TGF-β1 and 100 µg/ml HA (220 µM D.U.) or sHA3 (130 µM D.U.), 
pre-incubated for 2 h at 4 °C, for 5 min, 30 min and 60 min. Cells were washed with PBS and incubated in lysis 
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet-P40, 1 mM EDTA, 0.1% (v/v) SDS, 2 mM PMSF 
(AppliChem, Darmstadt, Germany), 0.1 mM aprotinin, 0.1 mM Na3VO4 and 5 mM NaF) at 4 °C for 10 min. 
Lysates were centrifuged at 13,000 × g for 30 min at 4 °C. Equal amounts of protein (20 µg) were subjected to 
12% SDS-polyacrylamide gels and subsequently transferred to nitrocellulose membranes (GE Healthcare, 
Freiburg Germany). The membranes were incubated with 5% (w/v) BSA in 25 mM Tris-buffered saline, pH 
8/0.5% (v/v) Tween-20 (TBST) or 5% (w/v) dry milk in TBST at RT for 2 h and primary antibody in TBST 
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containing 5% BSA at 4 °C overnight. The following primary antibodies were used: rabbit-anti-human TGF beta 
Receptor I (Phospho-Ser165) pAB (MBS859620, My Bio Source via Biozol Diagnostica Vertrieb GmbH, Eching, 
Germany), rabbit-anti-human TGF beta Receptor I pAB (PA5–14959, Thermo Scientific, Schwerte Germany), 
rabbit-anti-human phospho-Smad2 (Ser465/467) pAB (3101, Cell Signaling Technology (CST) via New England 
Biolabs, Frankfurt/Main, Germany), rabbit-anti-human phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) pAB 
(9101, CST) and mouse-anti-human GAPDH mAB (CB1001, Calbiochem via Merck Millipore, Darmstadt, 
Germany). All primary antibodies were diluted 1:1000. Horseradish peroxidase (HRP)-conjugated second-
ary anti-rabbit-IgG and anti-mouse-IgG (CST) in TBST containing 5% dry milk at a dilution of 1:2000 were 
used as secondary antibodies. Immune complexes were detected using Immobilon Western Chemiluminescent 
HRP Substrate (Merck Millipore) and visualized by enhanced chemiluminescence detection using a CCD cam-
era system (MF-ChemiBIS1.6 via Biostep Jahnsdorf, Germany). For re-blotting the membrane was incubated 
in stripping buffer (Thermo Scientific) at RT for 20 min. Afterwards the immune steps were repeated starting 
with dry milk incubation. Band signals were evaluated densitometrically using ImageQuantTM 5.1 software (GE 
Healthcare).
Statistical Analysis. All experiments were performed in triplicate and results are presented as mean ± stand-
ard deviation (SD) for SPR results and mean ± standard error of the mean (SEM) for Western Blot results. 
One-way ANOVA or two-way ANOVA with Bonferroni post-test were applied. P values < 0.05 were considered 
statistically significant.
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